RxDoctor Payments Data

Stacy Mielke

Family · Appleton, WINPI 1255037305

Payments from drug & device makers

$1,934in general payments, 2019–2025

Across 43 payments — averaging $44.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$997
  • AstraZeneca$169
  • Jazz Pharmaceuticals Inc.$142
  • United Therapeutics Corporation$125
  • Actelion Pharmaceuticals US, Inc.$116
  • Inogen, Inc.$79
  • plus $307 from 8 others

What the payments were for

  • Travel & lodging$69236%
  • Food & beverage$1,09957%
  • Education$1437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,934 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$38,363
Medicare patients
398
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$49,685
Stiolto RespimatTiotropium Br/Olodaterol Hcl50$26,243
Spiriva RespimatTiotropium Bromide27$14,035
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,006
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$8,913
Breo ElliptaFluticasone/Vilanterol13$5,242
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,631
Arnuity ElliptaFluticasone Furoate15$3,493
Albuterol Sulfate HfaAlbuterol Sulfate73$2,043
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$1,796
Modafinil25$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$62$67,332110 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$22$40,27877 claims
AstraZenecaBreztri Aerosphere$169$12,00618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →